Pfizer price target raised to $27 from $24 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Pfizer (PFE) to $27 from $24 and keeps a Neutral rating on the shares. With 2026 guidance already issued and only modest beat-and-raise potential expected, the earnings call is likely to be quiet, with focus shifting to the timing and framing of VESPER-3 obesity data, the analyst tells investors in a research note Incremental updates on the Lyme disease vaccine, mevro in prostate cancer, or sigvotatug vedotin in non-small cell lung cancer are expected to be more influential than the 4Q25 results, the firm says.